Forum 1
Novartis Campus
Basel 4056
Switzerland
41 61 324 11 11
https://www.sandoz.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 22,633
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Richard Saynor | Chief Executive Officer | N/A | N/A | 1967 |
Mr. Colin Michael Bond | Chief Financial Officer | N/A | N/A | 1960 |
Mr. Asaf Gal | Chief Technology Officer | N/A | N/A | 1969 |
Ms. Claire D'Abreu-Hayling | Chief Scientific Officer | N/A | N/A | 1964 |
Ms. Karen M. King | Head Global Investor Relations | N/A | N/A | N/A |
Ms. Ingrid Sollerer | General Counsel & Chief Compliance Officer | N/A | N/A | 1974 |
Ms. Tripti Jha | Chief People Officer | N/A | N/A | 1977 |
Mr. Francisco Ballester | President of International | N/A | N/A | 1961 |
Mr. Pierre Bourdage | Chief Commercial Officer | N/A | N/A | 1979 |
Dr. Glenn A. Gerecke Ph.D. | Chief Manufacturing & Supply Officer | N/A | N/A | 1959 |
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Sandoz Group AG’s ISS governance QualityScore as of 1 June 2024 is 3. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 9; Compensation: 2.